OB/GYN Clinical Alert – June 1, 2021
June 1, 2021
View Issues
-
Tranexamic Acid for the Prevention of Obstetric Hemorrhage
In this prospective, cohort, pharmacokinetic-pharmacodynamic (PKPD) dose-finding study by Ahmadzia and colleagues, 30 pregnant women (10 women in each study arm) received 5 mg/kg, 10 mg/kg, or 15 mg/kg doses of tranexamic acid for the prevention of postpartum hemorrhage. Advanced PKPD modeling demonstrated that 600 mg of tranexamic acid was the optimal dose to use in the prevention of postpartum hemorrhage.
-
Does Maternal BMI Influence the Success of Trial of Labor After Cesarean?
In this retrospective cohort study between May 2007 and April 2016, women undergoing a trial of labor after cesarean (TOLAC) were analyzed to determine if pre-pregnancy or delivery obesity status made an impact on TOLAC success. Overall, maternal body mass index did not have a significant effect on TOLAC success rates.
-
Anticholinergic Use for Three Months or More Increases Dementia Risk
There is a significant increase in dementia risk associated with the use of anticholinergic medications for three months or longer.
-
Is a Vacuum-Induced Device Effective for Control of Postpartum Hemorrhage?
In this multicenter study across 12 centers in the United States, a vacuum-induced intrauterine device successfully treated 94% of participants who experienced a postpartum hemorrhage with a median time of three minutes to control of bleeding.